tbuckley/cabot-search huggingface dataset:
Clarifying the treatment of nonarteritic anterior ischemic optic neuropathy
Authors: L. A. Levin
Journal: JAMA (1995)

Anterior ischemic optic neuropathy (AION), or optic nerve-head infarction, is the most common optic nerve disorder of the elderly except for glaucoma. There are two types of AION. The less common arteritic AION is associated with giant cell arteritis and was described more than 3000 years ago.<sup>1</sup>The pathophysiology of arteritic AION is well understood and consists of occlusion of the small posterior ciliary arteries supplying the anterior optic nerve. The diagnosis is suggested by the characteristic clinical findings of temporal ache or tenderness, polymyalgia rheumatica, and jaw claudication, as well as laboratory evidence of an elevated erythrocyte sedimentation rate. The diagnosis is proven by finding granulomatous inflammation with giant cells on biopsy of the temporal artery. Immediate high-dose corticosteroid therapy is mandatory, is usually effective prophylaxis for involvement of the other optic nerve, and may even reverse visual loss in occasional cases. See also p 625. In contrast,
Hasty Generalizations.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Home Visit
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial
Authors: D. V. Miller, R. B. Jenkins, W. L. Lingle, N. E. Davidson, P. A. Kaufman, S. Martino, S. R. Dakhil, E. A. Perez
Journal: Journal of Clinical Oncology (2004)

568 Background: Accurately and reliably identifying HER2/neu status is a critical priority in the treatment decision process. Current HER2 testing strategies include immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), but discrepancies between them (3+IHC and FISH-, 0–2+ IHC and FISH+) interfere with interpretation and patient management. We postulate that some of these discrepancies may reflect tumor heterogeneity, derived from focal HER2 amplified clones (FHAC) within a tumor. Methods: As part of the ongoing N9831 “Phase III trial of doxorubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab treatment for women with HER2 overexpressing or amplified node positive or high–risk node negative breast cancer” adjuvant Intergroup trial, breast tumors were evaluated for HER2 status by both IHC and FISH using HercepTest™ and PathVysion™ assays. Samples with FHAC were defined as containing 2% to 40% of cells demonstrating unequivocal amplification (cells with >10 HER2 signals and HER2:CEP17 ratio >5.0), regardless of the overall HER2:CEP17 ratio. HER2/FISH discordant cases were identified and the number with FHAC determined. Results: 2006 samples from 1738 patients were studied. 1169 cases demonstrated FISH amplification (HER2:CEP17 ratio ≥2) and were IHC positive (3+). 114 cases contained FISH amplification, but were IHC negative (0–1+) or equivocal (2+). 2 % of the IHC 3+/FISH amplified, 21% of the IHC 0–1+/FISH amplified, and 30% of the IHC 2+/FISH amplified cases contained FHAC (Table 1). Conclusions: The presence of FHAC seems to be a factor in a substantial number of cases exhibiting discordance between IHC and FISH evaluations of HER2 positivity. The prognosis and response to trastuzumab among patients with FHAC have yet to be determined. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly; Merck; Vysis, Inc.; Wyeth Merck Aventis Genentech
Public beliefs about causes and prevention of heart attacks
Authors: R. B. Shekelle
Journal: JAMA (1978)

Interviews with a probability sample of 617 adults in the Chicago area indicated widespread lack of information about major probable causes of heart attacks in persons younger than 60 years: 28% named cigarette smoking, 21% named high blood pressure, and 13% named cholesterol or fat in the diet or blood. Half did not name any of these risk factors, and only 1% named all three. Although three fourths believed that heart attacks are preventable, few named specific behaviors that would effectively reduce risk factors other than smoking. Sustained community-wide educational programs about reducing coronary risk factors are clearly needed and can be effective. (<i>JAMA</i>240:756-758, 1978)
Handbook of the Diagnosis and Treatment of Skin Diseases.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1957)

COMMITTEE ON MATERNAL WELFARERheumatic Heart Disease with Mitral Stenosis, Congestive Heart Failure and BronchopneumoniaA forty-three-year-old gravida 2, para 1, with rheumatic heart disease died thirty-five hours post partum.The previous pregnancy and delivery had been normal but had taken place eighteen years before. She was now working in a factory and continued to do so until she was about seven months pregnant, when the doctor, who had been seeing her since the sixth week of pregnancy, advised her to stop because of dyspnea and tachycardia. He also prescribed digitalis, 0.09 gm. (1 1/2 gr.) daily, for two weeks . . .
Rorschach science; readings in theory &amp;amp; method.
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study.
Authors: David J. Straus, Monika Długosz-Danecka, Sergiy Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Kerry J. Savage, Piotr Smolewski, Nancy L. Bartlett, Andrea Gallamini, Jan Andrzej Walewski, Rod Ramchandren, Pier Luigi Zinzani, Joseph M. Connors, Hina Jolin, Rachael Liu, Keenan Fenton, Michelle Fanale, John A. Radford
Journal: Journal of Clinical Oncology (2019)

7532 Background: The phase 3 ECHELON-1 study demonstrated that BV with AVD (A+AVD) was superior to ABVD for the frontline treatment of Stage 3/4 cHL. Maturing data from RATHL and SWOG S0816 show limitations to PET2-adapted strategies, including short and long-term toxicities in PET2+ patients (pts) switched to BEACOPP and still frequent relapse in PET2- pts. Pts in the RATHL trial with Stage 3/4 disease ≤60 yrs had a 3-yr PFS of 79.8% (82.1% PET2-); SWOG S0816 reported a 5-yr PFS of 74% (76% PET2-) in the same population. As an alternative to PET-adapted therapy, here we present a 3-year update of the ECHELON-1 study, including ITT PFS and outcomes by PET status. Methods: Pts with Stage 3/4 cHL were randomized 1:1 to receive up to six cycles of A+AVD (n=664) or ABVD (n=670). Interim PET scan after cycle 2 was conducted. All analyses of PFS are exploratory and per investigator assessment. Results: At a median follow-up of 37 months, analysis of PFS in the ITT population favors the A+AVD treatment arm (Table), with a 3-yr PFS of 83.1% for A+AVD vs 76.0% for ABVD; the 3-yr PFS for PET2- pts &lt;60 yrs was 87.2% vs 81.0%, respectively. Trend toward benefit for PET2+ pts &lt;60 yrs treated with A+AVD was also observed, with a 3-yr PFS of 69.2% vs 54.7% with ABVD. Data from prespecified subgroups and safety follow-up, including peripheral neuropathy, will be presented. Conclusions: Follow-up at 3-yrs demonstrates that frontline treatment of Stage 3/4 cHL with A+AVD provides a durable treatment benefit vs ABVD that is independent of PET2 status. While direct comparisons cannot be made, A+AVD compares favorably to PET-adapted strategies without requiring interim PET assessment, escalation of therapy, or bleomycin. Clinical trial information: NCT01712490. [Table: see text]
JAMA Psychiatry
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Kevin Brown, Amanda Ehrhardt, Iris Lo, Michaela Mark, M Newman, Suzanne Walker, Connie Manno, Sara Billings, Timothy Gray, Paul Ruich, Catherine Copyreaders, Stephanie Alden, Jane Beckmeyer, Jan Calayag, Mary Clavey, Paula Coerver-Connolly, Laura Glitman, Brandy King, Donna Patton, Editorial Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Williams, Fanny Brown, Lenette Gardner-Gullens, Erin Kato, Peter Kim, Rachell Lozano, Caroline Sietmann, Angelia Waltower, Elizabeth Scientifi, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Carrie Butt, Mary Ferkaluk, Emily Ling, Jesse Mcquarters, Daniel Morrow, Reuben Rios, Ronna Henry, Karen Bucher, Andy Rekito, Nick Reback, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Marketing Thornbury, Tricia Classifi, Thalia Moss, Susan Henning, Tiff Stevenson, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, David Baum, Ron Thomas, Elizabeth Solaro, Geoff Rey Flick, Rick Bell, Fergus Clare, Lindsay Dawson, Will English, Ellen Gibson, Mustafa Ishaq, Craig Mccaff Rey, Michael Mcgraw, Daniel Pickhardt, Romando Rossini, Stacy Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Karl Elvin, Nancy Essex, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Scott Curl, Diane Darnell, Jordynn Farrar, Colleen Kelly, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Binita Shah, Denise Steinhauser, Erin Van Dusen, Joe Advertising, Production Services, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Daniel Degroot, Euwanaha Joiner- Smith, Joshua Lane, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Mary Sieck, Sarah Subramanian, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Nathan Mitre, Patricia Panek, La Son Diggs, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Bernard Hengesbaugh, Dan Blazer, North Carolina, David Braff, La Jolla, Stephen California, Washington Dager, Atlanta Druss, Susan Georgia, New Essock, New York, Ellen York, James Frank, Maryland Harris, S Kenneth, Virginia Kendler, C Ronald, Kathleen Kessler, Maryland Merikangas, Judith Samples O'malley, Maryland Rapoport, F Charles, Myrna Reynolds, New Weissman, Charles York, St Zorumski, Shitij Kapur, Michael Owen, Fmed Sci, Naomi Wray, Roy Grinker Sr, Daniel Freedman, Jack Barchas, Joseph Coyle, Jennifer Urbano Blackford, Jennifer Laws, Woolf Nashville, Dost Öngür, Martin Paulus, Christine Konradi, Helena Chmura Kraemer, Palo Alto, Howard Bauchner
Journal: JAMA Psychiatry (2017)
Diagnosis and management of depression in children and young people: summary of updated NICE guidance
Authors: K. Hopkins, P. Crosland, N. Elliott, S. Bewley
Journal: BMJ (2015)

#### The bottom line Depression affects around 2.8% of children under the age of 13 and 5.6% of 13-18 year olds.1 Effective treatment is important because persistent depression is associated with serious complications, including poor school performance and social functioning,2 recurring depression in adulthood,3 and suicide.4 This article summarises recommendations from the updated National Institute for Health and Care Excellence (NICE) guideline on depression in children and young people.5 The update had a narrow remit—only recommendations on the choice of psychological therapy and the combination of antidepressant treatment with psychological therapy were considered. NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. Where the evidence was minimal, recommendations in the original guidance were based on the guideline development group's experience and opinion of what constitutes good practice. Changes to the original recommendations were based on evidence from updated systematic reviews on clinical and cost effectiveness. Evidence levels for the recommendations are given in italic in square brackets. ### Assessment and detection
Erratum
Journal: BMJ (1907)

SOCIETY Z ;&1scopical examination showed that the tumour in the breast was due to chronic mastitis, while the axillary tumour was a fibro-adenoma, and must have occurred either in an aberrant lobule or as a supernumerary breast.Dr. J. DE VILLE MATHER read a communication on the pathology of carcinoma of the cervix uteri.In some 47 cases of malignant disease of the cervix treated by vaginal hysterectomy the microscopical examination showed squamous epitheliomata in 37, glandular cancer in 6, and sarcoma in 4. Referring to sarcoma of the cervix in more detail, Dr. Mather showed one case of angio-sarcoma and another case where the growth was a mixture of round-celled sarcoma and squamous epithelioma.The author did not consider sarcoma of the
SPECIAL ARTICLE.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Gastrointestinal Disease: An Endoscopic Approach
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hospital Collaborative Creates Tools to Help Reduce Medication Errors
Authors: R. Voelker
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mitochondrial creatine kinase. A poor prognostic sign
Authors: C. J. Bark
Journal: JAMA (1980)

A serum creatine kinase (CK) isoenzyme band cathodic to MM, thought to represent mitochondrial CK, was found in eight patients in shock, six of whom died within 12 days. Severe tissue damage appears to be required to release this isoenzyme to detectable levels in the serum. (<i>JAMA</i>243:2058-2060, 1980)
NON SIBI SED MEDICINAE—II
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Martin J.B. Taphoorn, Martin J. van den Bent, Murielle Mauer, Andrew Bottomley
Journal: Journal of Clinical Oncology (2008)

baseline compared with reference values."Although one would expect that QoL in oligodendroglioma patients after surgery/biopsy is worse than in the general population, this statement cannot be verified by the reader because no relevant descriptive QoL data are presented (except for physical function) for the study cohorts, and no characteristics of patients participating in the QoL study (eg, patient age) are described.It would therefore be of great interest to make more raw QoL data from this important trial available to allow comparison with other groups of brain tumor patients.